Claire Deligne
Postdoctoral Researcher
Tenascin-C is an extracellular matrix protein which is overexpressed during inflammatory diseases such as malignant cancers. In metastatic breast cancer in particular, the expression of high levels of tenascin-C is associated with a dramatic decrease of the patient’s survival.
My project consists in using cell biology technics and tumour models to decipher how tenascin-C impacts the differentiation, the prognosis value and the polarization of the adaptive immune response within the microenvironment of primary and metastatic tumours.
Recent Publications
5-
Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients.
Deligne C. et al, (2015), Osteoarthritis Cartilage, 23, 1843 - 1852
-
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice.
Deligne C. et al, (2015), Leukemia, 29, 947 - 957
-
[The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination].
Deligne C. and Teillaud JL., (2013), Med Sci (Paris), 29, 57 - 63